Clinical Trials Logo
  1. Home
  2. Solid Tumors and Lymphomas
  3. NCT02392611

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Solid Tumors and Lymphomas Clinical Trial

Official title:
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer

Clinical Trial Summary

The primary objectives of this study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or recommended dose for phase 2 study (RDP2) of alobresib as a monotherapy in participants with advanced solid tumors and lymphomas, and in combination with exemestane or fulvestrant in participants with advanced estrogen receptor positive breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02392611
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 1
Start date March 16, 2015
Completion date October 11, 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03172936 - Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas Phase 1
Withdrawn NCT00457574 - Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas Phase 1